Last reviewed · How we verify
NCT04689724
Covid-19 Airway Management
trial in Covid-19_airways Management in 123 participants. Completed in 27 October 2021.
27 October 2021
Quick facts
| Lead sponsor | University Health Network, Toronto |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 123 |
| Start date | 10 August 2020 |
| Primary completion | 27 October 2021 |
| Estimated completion | 27 October 2021 |
| Sites | 1 location across Canada |
Conditions studied
- Covid-19_airways Management — all drugs for Covid-19_airways Management →
Sponsor
University Health Network, Toronto
Who can join
18 and older, any sex, with Covid-19_airways Management. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study has a retrospective and a prospective component. The retrospective component aims to review data of all airway management related SAEs in COVID 19 patients (between April and July 2020); hypoxemia, hypotension and cardiac arrest within 15 min of intubation. The prospective component aims to assess the incidence of COVID-19 infection in Airway Management Team members by means of an interview assessing their COVID19 status after participating in airway management in the period outlined above. This prospective interview component is starting in December 2020.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A specialized airway management team for COVID-19 patients: a retrospective study of the experience of two Canadian hospitals in Toronto.
Jarvis N, Schiavo S, Bartoszko J, Ma M, et al · · 2022 · cited 11× · PMID 34881407 · DOI 10.1007/s12630-021-02169-x
Verify or expand the search:
- PubMed search for NCT04689724
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University Health Network, Toronto trials
Trials by the same sponsor.
- NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
- NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
- NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
- NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
- NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04689724 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
- Last refreshed: 4 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04689724.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing